Profound Medical Corp. Files 8-K with Press Release
Ticker: PROF · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001628808
| Field | Detail |
|---|---|
| Company | Profound Medical Corp. (PROF) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, press-release
TL;DR
Profound Medical Corp. dropped an 8-K, likely with news in the press release.
AI Summary
On March 27, 2026, Profound Medical Corp. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements/Exhibits. The filing includes a press release, which is the primary document for this report. Specific financial figures or operational updates are not detailed in the provided filing information.
Why It Matters
This 8-K filing indicates Profound Medical Corp. is making a public disclosure, likely containing important information for investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant negative events or financial distress.
Key Players & Entities
- Profound Medical Corp. (company) — Filer of the 8-K report
- 0001628808 (company) — CIK number for Profound Medical Corp.
- 2026-03-27 (date) — Filing date and period of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to provide Financial Statements and Exhibits, including a press release.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted on March 27, 2026.
What document type is included as Exhibit 99.1?
Exhibit 99.1 is a press release.
What is the CIK number for Profound Medical Corp.?
The CIK number for Profound Medical Corp. is 0001628808.
What is the SIC code listed for Profound Medical Corp.?
The SIC code listed for Profound Medical Corp. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2026-03-27 08:18:43
Filing Documents
- f8k_032726.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-26-001971.txt ( ) — 220KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_032726_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On March 27, 2026, Profound Medical Corp. (the "Company" or "Profound") issued a press release announcing that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center's state-of-the-art MRI suite. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 27, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROFOUND MEDICAL CORP. Date: March 27, 2026 By: /s/ Rashed Dewan Rashed Dewan Chief Financial Officer